Agios Pharmaceuticals, Inc. (AGIO)

Profile

https://www.agios.com

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing medicines for rare diseases through its expertise in cellular metabolism. The company’s core commercial product is PYRUKYND (mitapivat), an oral pyruvate kinase activator used in hemolytic anemia associated with pyruvate kinase deficiency, with additional development in other hematologic and genetically defined disorders. Agios is also advancing investigational therapies for conditions such as thalassemia, sickle cell disease, and phenylketonuria, reflecting its emphasis on rare disease biology and precision medicine. The company operates as a specialized hematology and rare disease developer, combining drug discovery, clinical development, and commercialization capabilities to address unmet medical needs. Agios Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.